{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:21:20Z","timestamp":1786760480599,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40273-020-00948-w","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T01:02:23Z","timestamp":1597280543000},"page":"1007-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-4179","authenticated-orcid":false,"given":"Ning","family":"Kam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-196X","authenticated-orcid":false,"given":"Kanila","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-4297","authenticated-orcid":false,"given":"Ella","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-623X","authenticated-orcid":false,"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-3522","authenticated-orcid":false,"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"issue":"32","key":"948_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"9753","key":"948_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)61350-5.","journal-title":"Lancet"},{"issue":"14","key":"948_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Raber L, Mach F, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehx566.","journal-title":"Eur Heart J"},{"issue":"7","key":"948_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334. https:\/\/doi.org\/10.7326\/0003-4819-158-7-201304020-00004.","journal-title":"Ann Intern Med"},{"issue":"18","key":"948_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"948_CR6","unstructured":"Evolocumab [database on the internet]. Department of Health Pharmaceutical Benefits Scheme. https:\/\/www.pbs.gov.au\/medicine\/item\/10958R. Accessed 11 June 2020."},{"issue":"15","key":"948_CR7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1615758.","journal-title":"N Engl J Med"},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/PPA.S44646","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419\u201334. https:\/\/doi.org\/10.2147\/PPA.S44646.","journal-title":"Patient Prefer Adherence"},{"key":"948_CR9","volume-title":"Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran","author":"A von Treskow","year":"2020","unstructured":"von Treskow A, O\u2019Donnell M. Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran. Basel: Novartis; 2020."},{"issue":"16","key":"948_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"2","key":"948_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5694\/mja2.50142","volume":"211","author":"LA Simons","year":"2019","unstructured":"Simons LA. An updated review of lipid-modifying therapy. Med J Aust. 2019;211(2):87\u201392. https:\/\/doi.org\/10.5694\/mja2.50142.","journal-title":"Med J Aust"},{"issue":"4","key":"948_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397\u2013409. https:\/\/doi.org\/10.2165\/00019053-199813040-00003.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"948_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Force I-SMGRPT. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012.","journal-title":"Value Health"},{"key":"948_CR14","unstructured":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Department of Health. https:\/\/pbac.pbs.gov.au\/. Accessed 17 Mar 2020."},{"issue":"2","key":"948_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.18773\/austprescr.2017.014","volume":"40","author":"C Taylor","year":"2017","unstructured":"Taylor C, Jan S. Economic evaluation of medicines. Aust Prescr. 2017;40(2):76\u20138. https:\/\/doi.org\/10.18773\/austprescr.2017.014.","journal-title":"Aust Prescr"},{"key":"948_CR16","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton B, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"2","key":"948_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/eurjhf\/hfq194","volume":"13","author":"JJ Thune","year":"2011","unstructured":"Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail. 2011;13(2):148\u201353. https:\/\/doi.org\/10.1093\/eurjhf\/hfq194.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"948_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PW Wilson","year":"2012","unstructured":"Wilson PW, D\u2019Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695\u2013703.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2012.01.014.","journal-title":"Am J Med"},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ahj.2019.02.013","volume":"212","author":"MB Yudi","year":"2019","unstructured":"Yudi MB, Clark DJ, Farouque O, Andrianopoulos N, Ajani AE, Brennan A, et al. Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. Am Heart J. 2019;212:134\u201343. https:\/\/doi.org\/10.1016\/j.ahj.2019.02.013.","journal-title":"Am Heart J"},{"key":"948_CR20","volume-title":"General Record of Incidence of Mortality (GRIM) data","author":"Australian Institute of Health and Welfare","year":"2019","unstructured":"Australian Institute of Health and Welfare. General Record of Incidence of Mortality (GRIM) data. Canberra: Australian Institute of Health and Welfare; 2019."},{"key":"948_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319896648","author":"Z Ademi","year":"2020","unstructured":"Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prev Cardiol. 2020. https:\/\/doi.org\/10.1177\/2047487319896648.","journal-title":"Eur J Prev Cardiol"},{"key":"948_CR22","unstructured":"National Hospital Cost Data Collection Report; Public Sector, Round 22 (Financial Year 2017\u201318). Independent Hospital Pricing Authority; 2020."},{"key":"948_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319878953","author":"K Perera","year":"2019","unstructured":"Perera K, Ademi Z, Liew D, Zomer E. Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. Eur J Prev Cardiol. 2019. https:\/\/doi.org\/10.1177\/2047487319878953.","journal-title":"Eur J Prev Cardiol"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2019.01.037","volume":"285","author":"E Zomer","year":"2019","unstructured":"Zomer E, Liew D, Tonkin A, Trauer JM, Ademi Z. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: the Australian healthcare perspective. Int J Cardiol. 2019;285:1\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.037.","journal-title":"Int J Cardiol"},{"key":"948_CR25","unstructured":"Health expenditure Australia 2017\u201318. Canberra: Australian Institute of Health and Welfare; 2019."},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/1471-2458-12-398","volume":"12","author":"LJ Cobiac","year":"2012","unstructured":"Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12:398. https:\/\/doi.org\/10.1186\/1471-2458-12-398.","journal-title":"BMC Public Health"},{"key":"948_CR27","unstructured":"PBS Expenditure and Prescriptions Report 1 July 2018 to 30 June 2019. PBS; 2019. https:\/\/www.pbs.gov.au\/info\/statistics\/expenditure-prescriptions\/pbs-expenditure-and-prescriptions-report."},{"issue":"2","key":"948_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","volume":"2","author":"EF Lewis","year":"2014","unstructured":"Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail. 2014;2(2):159\u201365. https:\/\/doi.org\/10.1016\/j.jchf.2013.12.003.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"948_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10198-006-0002-9","volume":"8","author":"P Lindgren","year":"2007","unstructured":"Lindgren P, Kahan T, Poulter N, Buxton M, Svarvar P, Dahlof B, et al. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ. 2007;8(1):25\u201330. https:\/\/doi.org\/10.1007\/s10198-006-0002-9.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"948_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jval.2011.09.004","volume":"15","author":"HF van Stel","year":"2012","unstructured":"van Stel HF, Busschbach JJ, Hunink MG, Buskens E. Impact of secondary cardiovascular events on health status. Value Health. 2012;15(1):175\u201382. https:\/\/doi.org\/10.1016\/j.jval.2011.09.004.","journal-title":"Value Health"},{"key":"948_CR31","unstructured":"Guide to the Methods of Technology Appraisal Report. London: National Institute for Health and Care Excellence; 2013."},{"key":"948_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/CEOR.S63187","volume":"6","author":"HC Wijeysundera","year":"2014","unstructured":"Wijeysundera HC, Farshchi-Zarabi S, Witteman W, Bennell MC. Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature. Clinicoecon Outcomes Res. 2014;6:253\u201368. https:\/\/doi.org\/10.2147\/CEOR.S63187.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"5","key":"948_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361\u20137. https:\/\/doi.org\/10.1007\/s40273-013-0032-y.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"948_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-018-0671-0","volume":"36","author":"MJ Korman","year":"2018","unstructured":"Korman MJ, Retterstol K, Kristiansen IS, Wisloff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. 2018;36(9):1031\u201341. https:\/\/doi.org\/10.1007\/s40273-018-0671-0.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"948_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","volume":"36","author":"LC Edney","year":"2018","unstructured":"Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the australian health system. Pharmacoeconomics. 2018;36(2):239\u201352. https:\/\/doi.org\/10.1007\/s40273-017-0585-2.","journal-title":"Pharmacoeconomics"},{"key":"948_CR36","unstructured":"ClinicalTrials.gov. Trial to Assess the effect of long term dosing of inclisiran in subjects with high CV risk and elevated LDL-C (ORION-8). Bethesda. ClinicalTrials.gov 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03814187. Accessed 19 May 2020."},{"issue":"7","key":"948_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.18553\/jmcp.2012.18.7.527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339. https:\/\/doi.org\/10.18553\/jmcp.2012.18.7.527.","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"948_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/archinternmed.2010.495","volume":"171","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814\u201322. https:\/\/doi.org\/10.1001\/archinternmed.2010.495.","journal-title":"Arch Intern Med"},{"key":"948_CR39","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.2147\/PPA.S149423","volume":"12","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Prefer Adherence. 2018;12:2263\u20136. https:\/\/doi.org\/10.2147\/PPA.S149423.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"948_CR40","doi-asserted-by":"publisher","first-page":"e016982","DOI":"10.1136\/bmjopen-2017-016982","volume":"8","author":"RL Cutler","year":"2018","unstructured":"Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. https:\/\/doi.org\/10.1136\/bmjopen-2017-016982.","journal-title":"BMJ Open"},{"issue":"12","key":"948_CR41","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s41587-019-0351-4","volume":"37","author":"C Sheridan","year":"2019","unstructured":"Sheridan C. PCSK9-gene-silencing, cholesterol-lowering drug impresses. Nat Biotechnol. 2019;37(12):1385\u20137. https:\/\/doi.org\/10.1038\/s41587-019-0351-4.","journal-title":"Nat Biotechnol"},{"issue":"25","key":"948_CR42","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"7","key":"948_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","volume":"4","author":"SA Murphy","year":"2019","unstructured":"Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4(7):613\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2019.0886.","journal-title":"JAMA Cardiol"},{"key":"948_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ijcard.2016.07.201","volume":"222","author":"PC Deedwania","year":"2016","unstructured":"Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, et al. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016;222:548\u201356. https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.201.","journal-title":"Int J Cardiol"},{"issue":"3","key":"948_CR45","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/STROKEAHA.107.501361","volume":"39","author":"A Nassief","year":"2008","unstructured":"Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke. 2008;39(3):1042\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.107.501361.","journal-title":"Stroke"},{"issue":"1","key":"948_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1055\/s-0040-1701639","volume":"29","author":"A Pradhan","year":"2020","unstructured":"Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Triglycerides and cardiovascular outcomes\u2014can we REDUCE-IT? Int J Angiol. 2020;29(1):2\u201311. https:\/\/doi.org\/10.1055\/s-0040-1701639.","journal-title":"Int J Angiol"},{"issue":"1","key":"948_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","volume":"18","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18(1):122. https:\/\/doi.org\/10.1186\/s13063-017-1870-2.","journal-title":"Trials"},{"issue":"3","key":"948_CR48","doi-asserted-by":"publisher","first-page":"e0152030","DOI":"10.1371\/journal.pone.0152030","volume":"11","author":"J Stevanovi\u0107","year":"2016","unstructured":"Stevanovi\u0107 J, Pechlivanoglou P, Kampinga MA, Krabbe PF, Postma MJ. Multivariate meta-analysis of preference-based quality of life values in coronary heart disease. PLoS One. 2016;11(3):e0152030. https:\/\/doi.org\/10.1371\/journal.pone.0152030.","journal-title":"PLoS One"},{"issue":"4","key":"948_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422\u201337. https:\/\/doi.org\/10.1002\/hec.1481.","journal-title":"Health Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-020-00948-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T18:59:22Z","timestamp":1723402762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-020-00948-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00948-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"13 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) received no financial support for the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ning Kam, Kanila Perera and Zanfina Ademi have no conflicts of interest to declare. Ella Zomer has received grants from Amgen, AstraZeneca, Pfizer and Shire, outside the submitted work. Danny Liew declares grant support from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, CSL-Behring, Novartis, Pfizer, Sanofi and Shire, and past participation in advisory boards at Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer and Sanofi, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Custom code is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ZA conceived the idea and NK, KP, EZ and DL contributed to the design of the work. All authors contributed to the acquisition, analysis or interpretation of data for the work. NK drafted the manuscript. ZA, EZ and DL critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work ensuring integrity and accuracy.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Ethics approval was not required as this study relied on published and publicly available data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}